trial · primary record
Serplulimab + Fruquintinib
Non-Clear Cell Renal Cell Carcinoma (nccRCC)
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 108 |
| Primary completion | 2032-12-30 |
| Primary endpoint | 2-Year Recurrence-Free Survival (RFS) Rate |
| Registry ID | NCT07904156 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:49.041Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07904156
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.